These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis.
    Author: Blair HA.
    Journal: Paediatr Drugs; 2021 Nov; 23(6):601-608. PubMed ID: 34665445.
    Abstract:
    Subcutaneous secukinumab (Cosentyx®) is a recombinant, fully human, immunoglobulin (Ig) G1κ monoclonal antibody targeted against interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriasis. Secukinumab is approved in the EU and the USA for the treatment of moderate to severe plaque psoriasis in pediatric patients aged ≥ 6 years. In pivotal phase III trials in pediatric patients aged 6 to < 18 years, both low (75-150 mg) and high (75-300 mg) doses of secukinumab were significantly better than placebo and numerically better than etanercept at week 12 in terms of the proportion of patients achieving ≥ 75% improvement from baseline in Psoriasis Area and Severity Index and significantly better than placebo and etanercept in terms of the proportion of patients achieving an Investigator's Global Assessment score of 0 or 1. The clinical efficacy of secukinumab observed during the first 12 weeks of treatment was maintained over the longer term. Treatment with secukinumab improved health-related quality of life and was generally well tolerated. In conclusion, secukinumab represents a valuable new addition to the limited treatment options available for children and adolescents with moderate to severe plaque psoriasis. Plaque psoriasis is a chronic, inflammatory skin condition that can have a negative impact on the quality of life of affected children and their families. Compared with the expanding treatment options for adults with plaque psoriasis, the number of approved medications for pediatric plaque psoriasis is relatively low. Subcutaneous secukinumab (Cosentyx®) is one of several targeted biologic agents that have recently been approved for treating plaque psoriasis in pediatric patients. Secukinumab binds to IL-17A and inhibits the release of proinflammatory cytokines and chemokines. Treatment with secukinumab provided fast and durable skin clearance and continuous improvements in health-related quality of life in children and adolescents aged 6 to < 18 years with moderate to severe plaque psoriasis. The benefits of secukinumab were maintained over the longer term and the drug was generally well tolerated. With a convenient 4-weekly maintenance dosing regimen and the option of caregiver administration, secukinumab is a valuable option for the treatment of moderate to severe pediatric plaque psoriasis.
    [Abstract] [Full Text] [Related] [New Search]